INBXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Inhibrx Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$89.79−0.04 (-0.04%)
Close on Oct 19, 2026
- Market cap
- $1.41B
- P/E (TTM)
- –
- Dividend yield
- –
Inhibrx Biosciences, Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | TTM Q2 23 | TTM Q1 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| License fee revenue | $1.30M | – | – | – | $200.00K | $1.73M | $1.85M | $1.78M | $1.80M | $440.00K | $599.00K | $1.28M | 100.0% | +550.0% |
| License fee revenue | $1.30M | – | – | – | $200.00K | – | – | – | $1.80M | $440.00K | $599.00K | $1.28M | 100.0% | +550.0% |
| Grant revenue | – | – | – | – | – | – | – | – | $0 | $0 | $0 | $0 | – | – |
By region
From the segment and revenue-disaggregation notes of Inhibrx Biosciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.